Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)02466-3
Affiliations:
8
Authors:
13
Go to article
Institutions Authors Share
University of California, Davis (UC Davis), United States of America (USA)
9.750000
 0.75
UC Davis Health, United States of America (USA)
3.250000
 0.25
Interested in Reproductive Medicine?